CA2852397A1 - Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii - Google Patents

Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii Download PDF

Info

Publication number
CA2852397A1
CA2852397A1 CA2852397A CA2852397A CA2852397A1 CA 2852397 A1 CA2852397 A1 CA 2852397A1 CA 2852397 A CA2852397 A CA 2852397A CA 2852397 A CA2852397 A CA 2852397A CA 2852397 A1 CA2852397 A1 CA 2852397A1
Authority
CA
Canada
Prior art keywords
factor viii
body weight
sulfated glycosaminoglycan
fviii
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2852397A
Other languages
English (en)
French (fr)
Inventor
Hubert Metzner
Sabine ZOLLNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
CSL Behring GmbH Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring GmbH Deutschland filed Critical CSL Behring GmbH Deutschland
Publication of CA2852397A1 publication Critical patent/CA2852397A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA2852397A 2011-10-18 2012-10-18 Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii Abandoned CA2852397A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161548606P 2011-10-18 2011-10-18
EP11185648 2011-10-18
EP11185648.0 2011-10-18
US61/548,606 2011-10-18
PCT/EP2012/070615 WO2013057167A1 (en) 2011-10-18 2012-10-18 Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii

Publications (1)

Publication Number Publication Date
CA2852397A1 true CA2852397A1 (en) 2013-04-25

Family

ID=48140372

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2852397A Abandoned CA2852397A1 (en) 2011-10-18 2012-10-18 Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii

Country Status (10)

Country Link
US (1) US9393289B2 (enExample)
EP (1) EP2768522B1 (enExample)
JP (1) JP6072810B2 (enExample)
KR (1) KR20140083036A (enExample)
CN (1) CN103889445A (enExample)
AU (1) AU2012318279B2 (enExample)
CA (1) CA2852397A1 (enExample)
DK (1) DK2768522T3 (enExample)
ES (1) ES2600081T3 (enExample)
WO (1) WO2013057167A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140083035A (ko) 2011-10-18 2014-07-03 체에스엘 베링 게엠베하 인자 ｖｉｉｉ의 생체이용률을 증가시키기 위한 황산화 글리코사미노글리칸과 하이알루로니다제의 병용 사용
KR20170010895A (ko) 2014-06-06 2017-02-01 옥타파마 아게 인자 ⅷ 및 폰 빌레브란트 인자 펩티드를 포함하는 조제
CN114106179B (zh) * 2014-09-12 2025-04-08 加利福尼亚大学董事会 巨胞饮人类抗cd46抗体和靶向癌症疗法
AU2016215124B2 (en) 2015-02-06 2020-08-06 The University Of North Carolina At Chapel Hill Optimized human clotting Factor VIII gene expression cassettes and their use
SE539575C2 (en) * 2015-07-30 2017-10-17 Tx Medic Ab Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
JPH0788399B2 (ja) 1985-04-12 1995-09-27 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド 新規プロコアギュラント蛋白質
FR2673632A1 (fr) 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A0 (en) 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
EP0910628B1 (en) 1996-04-24 2006-03-08 The Regents of The University of Michigan Inactivation resistant factor viii
WO2000024759A1 (en) 1998-10-23 2000-05-04 The Trustees Of The University Of Pennsylvania Systemic delivery of gene products via skin
NZ530131A (en) 2001-06-15 2005-12-23 Andre C Gene therapy for hemophilia A
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
PT1624891E (pt) 2003-05-06 2010-01-05 Syntonix Pharmaceuticals Inc Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
AU2008323768A1 (en) * 2007-11-09 2009-05-14 Baxter Healthcare S.A. Modified recombinant Factor VIII and von Willebrand Factor and methods of use
CN103497247A (zh) * 2008-02-27 2014-01-08 诺沃—诺迪斯克有限公司 缀合的因子viii分子
AU2010284977A1 (en) 2009-08-20 2012-03-29 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
WO2011095604A1 (en) * 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins

Also Published As

Publication number Publication date
DK2768522T3 (en) 2016-11-14
AU2012318279B2 (en) 2015-06-04
EP2768522B1 (en) 2016-07-27
CN103889445A (zh) 2014-06-25
KR20140083036A (ko) 2014-07-03
ES2600081T3 (es) 2017-02-07
JP2014530246A (ja) 2014-11-17
JP6072810B2 (ja) 2017-02-01
EP2768522A1 (en) 2014-08-27
US20140315815A1 (en) 2014-10-23
WO2013057167A1 (en) 2013-04-25
AU2012318279A1 (en) 2013-05-02
US9393289B2 (en) 2016-07-19

Similar Documents

Publication Publication Date Title
US10881717B2 (en) Method for improving the stability of purified Factor VIII after reconstitution
US9107902B2 (en) Use of VWF stabilized FVIII preparations and of VWF preparations without FVIII for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
EP2768521B1 (en) Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor viii
EP2768522B1 (en) Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii
KR20210134642A (ko) 재조합 vwf (rvwf)를 이용한 예방 치료 방법
HK1197648A (en) Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii
HK1197648B (en) Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii
HK1197649B (en) Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor viii

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170918

FZDE Dead

Effective date: 20191018